Mankind Pharma IPO - One Of The Largest Domestic Pharma Companies In India: Anand Rathi

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. .Anand Rathi's IPO Report.Being the second company to launch Dydroboon (Rs 1.5 billion sales in FY22), Mankind Pharma Ltd. plans to develop and launch such new chemical entities. GPR119, an anti-diabetic molecule is in phase-I clinical trials. The company is on track to developing several antiallergic and anti-cancer biosimilars. Focus on acquisitions, expanding its chronic therapies. Sales of chronic therapies (33% of FY22 revenues) clocked an 18% compound annual growth rate over FY20-22, outpacing the Indian pharma market’s 11%. The recently acquired pharma formulations (transplants, oncology) from Panacea Biotec, and Daffy (derma) and Combihale (respiratory) from Dr. Reddy’s Laboratories Ltd. would boost growth.Further growth would be led by launches in SGLT2 inhibitors, gliptins, cardiac, anti-epileptic, antidepressant anxiolytics. Strengthening position in class I cities. Mankind explores potential to grow operations in class I cities (~53% of domestic sales versus the IPM’s 64%), which grew a 22% CAGR over FY20-22 outpacing the IPM’s 10%. This will be strengthened by the recently launched specialty categories in cardiodiabetology, cardio-vasculars, respiratories, transplants, and oncology. We expect the company’s strong set of brands, focused approach to its chronic portfolio via recent acquisitions, launches and differentiated pipeline products to be key positives. Risks: Addition of National List of Essential Medicines lists, rise in raw material prices..Click on the attachment to read the full IPO report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Mankind Pharma IPO - One Of The Largest Domestic Pharma Companies In India: Anand Rathi

Mankind Pharma will launch its maiden public offering on April 25, 2023.

Choose a plan